Yew N S, Cheng S H
Genzyme Corporation, Framingham, MA 01701-9322, USA.
Curr Opin Mol Ther. 2001 Aug;3(4):399-406.
Deficiencies in one or several of the numerous degradative enzymes that reside in the lysosome often result in one of many clinically severe diseases, almost all of which have no currently available therapy. Although bone marrow transplantation, enzyme replacement and substrate inhibition therapies are being considered, gene therapy represents an increasingly attractive approach, particularly for those lysosomal storage diseases with neurological manifestations. This review summarizes the most recent advances in developing gene therapies for this large and heterogeneous group of disorders.
溶酶体中存在的多种降解酶中一种或几种的缺陷通常会导致许多临床上严重的疾病之一,几乎所有这些疾病目前都没有可用的治疗方法。尽管正在考虑进行骨髓移植、酶替代和底物抑制疗法,但基因疗法是一种越来越有吸引力的方法,特别是对于那些有神经学表现的溶酶体贮积病。这篇综述总结了针对这一庞大且异质性疾病群体开发基因疗法的最新进展。